Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high-resolution analysis.


Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
03 2021
Historique:
received: 23 06 2020
revised: 20 11 2020
accepted: 24 12 2020
pubmed: 29 12 2020
medline: 8 7 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

There are many studies on the polymorphism of the HLA system in healthy donor populations, such as registries of unrelated bone marrow donors. Investigations on the characterization of the HLA complex in hematopoietic stem cell transplant (HSCT) patients, however, are scarce, at least in the Spanish population. This study presents a large-scale analysis of allelic diversity and HLA distribution at a high-resolution level in 2886 patients undergoing HSCT in Spanish centres of the "Grupo Español de Trasplante Hematopoyético y Terapia Celular" during a period of 11 years. Allelic diversity analysis identified 67 HLA-A, 133 HLA-B, 60 HLA-C, 63 HLA-DRB1, 24 HLA-DQB1 and 27 HLA-DPB1 different alleles. Rare alleles were detected among which 33 alleles had not been reported in the European catalog of common and well-documented HLA alleles. Regarding the distribution of five genes-haplotypes, it was observed that the five most frequent extended haplotypes found in our population were between the most common in other Spanish populations, both in patients and in healthy subjects. However, some particular haplotypes were also detected. Bilocus associations HLA-C ~ B and -DRB1 ~ DQB1 were analyzed in order to predict the probability of finding 10/10 matched donors in registries. We found HLA-B alleles showing a great diversity of combinations with HLA-C alleles and unusual associations involving a negative predicting factor. In the field of adoptive therapies, our work supports the necessity to expand further research of TCR-engineered cells, adoptive transfer of virus-specific T-cells and vaccines to target HLA alleles other than A*02:01. HLA alleles such as A*01:01, A*03:01, A*24:02, B*44:03, B*07:02 or B*51:01, might be considered new targets due to its high frequency in our population.

Identifiants

pubmed: 33369244
doi: 10.1111/tan.14179
doi:

Substances chimiques

HLA-A Antigens 0
HLA-B Antigens 0
HLA-DRB1 Chains 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-213

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Mungall AJ, Palmer SA, Sims SK, et al. The DNA sequence and analysis of human chromosome 6. Nature. 2003;425(6960):805-811. https://doi.org/10.1038/nature02055.
Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan marrow donor program. N Engl J Med. 1998;339(17):1177-1185. https://doi.org/10.1056/NEJM199810223391701.
Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235-2241. https://doi.org/10.1182/blood-2007-02-072405.
Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976-2980. https://doi.org/10.1182/blood-2004-04-1674.
Arora M, Weisdorf DJ, Spellman SR, et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009;27(10):1644-1652. https://doi.org/10.1200/JCO.2008.18.7740.
Tiercy J-M. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101(6):680-687. https://doi.org/10.3324/haematol.2015.141119.
Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol. 2006;6(12):883-894. https://doi.org/10.1038/nri1977.
van Leeuwen EMM, Remmerswaal EBM, Heemskerk MHM, ten Berge IJM, van Lier RAW. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood. 2006;108(9):3121-3127. https://doi.org/10.1182/blood-2006-03-006809.
Withers B, Clancy L, Burgess J, et al. Establishment and operation of a third-party virus-specific T cell Bank within an allogeneic stem cell transplant program. Biol Blood Marrow Transplant. 2018;24(12):2433-2442. https://doi.org/10.1016/j.bbmt.2018.08.024.
Withers B, Blyth E, Clancy LE, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2017;1(24):2193-2205. https://doi.org/10.1182/bloodadvances.2017010223.
Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360-4367. https://doi.org/10.1182/blood-2010-01-262089.
Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113-5123. https://doi.org/10.1182/blood-2013-02-486324.
Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human Herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35(31):3547-3557. https://doi.org/10.1200/JCO.2017.73.0655.
Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after Allo-HSCT. Leukemia. 2017;31(10):2161-2171. https://doi.org/10.1038/leu.2017.16.
Qasim W, Gilmour K, Zhan H, et al. Interferon-γ capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2013;161(3):449-452. https://doi.org/10.1111/bjh.12251.
Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644-2656. https://doi.org/10.1182/blood-2011-08-371971.
Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell. 2018;9(3):254-266. https://doi.org/10.1007/s13238-016-0367-1.
La Rosa C, Longmate J, Lingaraju CR, et al. Rapid Acquisition of Cytomegalovirus-Specific T Cells with a differentiated phenotype, in Nonviremic hematopoietic stem transplant recipients vaccinated with CMVPepVax. Biol Blood Marrow Transplant. 2019;25(4):771-784. https://doi.org/10.1016/j.bbmt.2018.12.070.
Montoro J, Piñana JL, Sanz J, Guerreiro M. T lymphocytes as therapeutic arsenal for patients with hematological malignancies. Curr Opin Oncol. 2018;30(6):1. https://doi.org/10.1097/CCO.0000000000000481.
Qasim W. Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019;94(S1):S50-S54. https://doi.org/10.1002/ajh.25399.
Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs. 2017;31(6):473-481. https://doi.org/10.1007/s40259-017-0247-0.
Nunes E, Heslop H, Fernandez-Vina M, et al. Definitions of histocompatibility typing terms. Blood. 2011;118(23):e180-e183. https://doi.org/10.1182/blood-2011-05-353490.
Bochtler W, Maiers M, Oudshoorn M, et al. World marrow donor association guidelines for use of HLA nomenclature and its validation in the data exchange among hematopoietic stem cell donor registries and cord blood banks. Bone Marrow Transplant. 2007;39(12):737-741. https://doi.org/10.1038/sj.bmt.1705672.
Martín M, Reinoso R, Martino M, Corell A. GECLID: una iniciativa de la Sociedad Española de Inmunología con beneficios para todos. Inmunología. 2011;30(1):21-29.
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291-455. https://doi.org/10.1111/j.1399-0039.2010.01466.x.
Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G. PyPop update-a software pipeline for large-scale multilocus population genomics. Tissue Antigens. 2007;69:192-197. https://doi.org/10.1111/j.1399-0039.2006.00769.x.
Bettencourt BF, Santos MR, Fialho RN, et al. Evaluation of two methods for computational HLA haplotypes inference using a real dataset. BMC Bioinformatics. 2008;9(1):68. https://doi.org/10.1186/1471-2105-9-68.
Excoffier L, Lischer H. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and windows. Mol Ecol Resour. 2010;10(3):564-567. https://doi.org/10.1111/j.1755-0998.2010.02847.x.
Hedrick PW. Gametic disequilibrium measures: proceed with caution. Genetics. 1987;117(2):331-341.
Sanchez-Mazas A, Nunes JM, Middleton D, et al. Common and well-documented HLA alleles over all of Europe and within European sub-regions: a catalogue from the European Federation for Immunogenetics. HLA. 2017;89(2):104-113. https://doi.org/10.1111/tan.12956.
Mack SJ, Cano P, Hollenbach JA, et al. Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens. 2013;81(4):194-203. https://doi.org/10.1111/tan.12093.
Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA Database. Nucleic Acids Res. 2020;48(D1):D948-D955. https://doi.org/10.1093/nar/gkz950.
Hurley CK, Oudshoorn M, Setterholm M. Donor registries and search strategies. Methods Mol Biol. 2012;882:531-547. https://doi.org/10.1007/978-1-61779-842-9_30.
Balas A, García-Sánchez F, Vicario JL. Allelic and haplotypic HLA frequency distribution in Spanish hematopoietic patients. Implications for unrelated donor searching. Tissue Antigens. 2011;77(1):45-53. https://doi.org/10.1111/j.1399-0039.2010.01578.x.
Muro M, Marín L, Torío A, et al. HLA polymorphism in the Murcia population (Spain): in the cradle of the archaeologic Iberians. Hum Immunol. 2001;62(9):910-921. https://doi.org/10.1016/s0198-8859(01)00290-7.
Martinez-Laso J, Ramirez-Puga A, Rivas-García E, et al. North African-Mediterranean HLA genetic contribution in a population of the kidney transplant waiting list patients of canary origin (gran Canaria). HLA. 2018;92(1):12-23. https://doi.org/10.1111/tan.13298.
Alcoceba M, Marín L, Balanzategui A, et al. Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-Central Spain). Tissue Antigens. 2011;78(4):249-255. https://doi.org/10.1111/j.1399-0039.2011.01766.x.
Romòn I, Montes C, Ligeiro D, et al. Mapping the HLA diversity of the Iberian Peninsula. Hum Immunol. 2016;77(10):832-840. https://doi.org/10.1016/j.humimm.2016.06.023.
Montero-Martín G, Mallempati KC, Gangavarapu S, et al. High-resolution characterization of allelic and haplotypic HLA frequency distribution in a Spanish population using high-throughput next-generation sequencing. Hum Immunol. 2019;80(7):429-436. https://doi.org/10.1016/j.humimm.2019.02.005.
Pingel J, Solloch UV, Hofmann JA, Lange V, Ehninger G, Schmidt AH. High-resolution HLA haplotype frequencies of stem cell donors in Germany with foreign parentage: how can they be used to improve unrelated donor searches? Hum Immunol. 2013;74(3):330-340. https://doi.org/10.1016/j.humimm.2012.10.029.
Gonzalez-Galarza FF, McCabe A, Santos EJMD, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020;48(D1):D783-D788. https://doi.org/10.1093/nar/gkz1029.
Mack SJ, Gourraud P-A, Single RM, Thomson G, Hollenbach JA. Analytical methods for immunogenetic population data. Methods Mol Biol. 2012;882:215-244. https://doi.org/10.1007/978-1-61779-842-9_13.
Enrich E, Campos E, Martorell L, et al. HLA-A, -B, -C, -DRB1, and -DQB1 allele and haplotype frequencies: an analysis of umbilical cord blood units at the Barcelona cord blood Bank. HLA. 2019;94(4):347-359. https://doi.org/10.1111/tan.13644.
Solberg OD, Mack SJ, Lancaster AK, et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol. 2008;69(7):443-464. https://doi.org/10.1016/j.humimm.2008.05.001.
Meyer D, Single RM, Mack SJ, Erlich HA, Thomson G. Signatures of demographic history and natural selection in the human major histocompatibility complex loci. Genetics. 2006;173(4):2121-2142. https://doi.org/10.1534/genetics.105.052837.
Sanchez-Mazas A. An apportionment of human HLA diversity. Tissue Antigens. 2007;69(Suppl 1):198-202. https://doi.org/10.1111/j.1399-0039.2006.00802.x.
Pedron B, Duval M, Elbou OM, et al. Common genomic HLA haplotypes contributing to successful donor search in unrelated hematopoietic transplantation. Bone Marrow Transplant. 2003;31(6):423-427. https://doi.org/10.1038/sj.bmt.1703876.
Pédron B, Guérin-El Khourouj V, Dalle J-H, et al. Contribution of HLA-A/B/C/DRB1/DQB1 common haplotypes to donor search outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1612-1618. https://doi.org/10.1016/j.bbmt.2011.03.009.
Tiercy J-M, Nicoloso G, Passweg J, et al. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplant. 2007;40(6):515-522. https://doi.org/10.1038/sj.bmt.1705787.
Eberhard H-P, Müller CR. The impact of HLA-C matching on donor identification rates in a European-Caucasian population. Front Immunol. 2014;5:501. https://doi.org/10.3389/fimmu.2014.00501.
Ikeda N, Kojima H, Nishikawa M, et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens. 2015;85(4):252-259. https://doi.org/10.1111/tan.12536.
Bettens F, Nicoloso de Faveri G, Tiercy J-M. HLA-B51 and haplotypic diversity of B-Cw associations: implications for matching in unrelated hematopoietic stem cell transplantation. Tissue Antigens. 2009;73(4):316-325. https://doi.org/10.1111/j.1399-0039.2009.01215.x.
Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol. 2013;74(10):1313-1320. https://doi.org/10.1016/j.humimm.2013.06.025.

Auteurs

Manuel Guerreiro (M)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Dolores Planelles (D)

Department of Histocompatibility, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain.

Cristóbal Aguilar-Gallardo (C)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

José Ignacio Lorenzo (JI)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Juan Montoro (J)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Jaime Sanz (J)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Aitana Balaguer (A)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Inés Gómez (I)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Pilar Solves (P)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Ariadna Pérez (A)

Haematology Department, Hospital Clínico Universitario. Fundación INCLIVA, Valencia, Spain.

Miguel Blanquer (M)

Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.
Cell Therapy Unit, IMIB-University Hospital Virgen de la Arrixaca, Faculty of Medicine, University of Murcia, Murcia, Spain.

Ildefonso Espigado (I)

Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.
Haematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Carlos Solano (C)

Haematology Department, Hospital Clínico Universitario. Fundación INCLIVA, Valencia, Spain.
Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.

José Luis Piñana (JL)

Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.
Hematology Division, CIBERONC, Instituto Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH